Gent

• Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended
  2022-502339-20-00 4 2023-11-15 Squamous cell carcinoma of head and neck
• Open-Label Extension (OLE) Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren’s Syndrome (pSS) Ended
  2023-503915-14-00 4 2023-11-15 Primary Sjögren's Syndrome
• MK-1084 Single and Multiple Dose Healthy Participant Study Ended
  2023-507529-41-00 3 2023-11-07 ​​Solid tumor cancer and lung cancer​​
• A Phase 3 Randomized Double-blind Controlled Study to Evaluate the Immunogenicity, Safety, and Reactogenicity of ExPEC9V and High-dose Quadr … Ended
  2023-504168-40-00 5 2023-11-06 Prevention of invasive extraintestinal pathogenic Escherichia coli (Ex
• Single Rising Dose Study of MK-1708 in Healthy Participants Ended
  2023-506946-21-00 1 2023-10-24 Amyotrophic lateral sclerosis and Alzheimer’s disease
• A Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis Ended
  2022-501621-20-00 5 2023-10-02 Prurigo Nodularis
• A Ph3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia: The ENTRUST study Ended
  2023-503576-25-00 5 2023-09-22 Severe Hypertriglyceridemia
• A Study to Investigate Bowel Urgency in Adults with Moderately to Severely Active Ulcerative Colitis Treated with Mirikizumab Ended
  2022-502393-16-00 5 2023-09-06 Moderately to Severely Active Ulcerative Colitis
• A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis Ended
  2022-502647-35-00 4 2023-09-01 Non-alcoholic steatohepatitis
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• A study to evaluate Intravitreal JNJ-81201887(AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary … Ended
  2022-500746-16-00 4 2023-08-11 Geographic Atrophy
• A dose-escalation and expansion study of the safety and pharmacokinetics of XB002 as single-agent and combination therapy in subjects with i … Ended
  2023-508267-69-00 3 2023-08-11 Subjects with Aadvanced solid tumors for whom life-prolonging therapie
• A single-arm, open-label study to evaluate the efficacy and safety of ABBV-668 in subjectswith moderate to severe ulcerative colitis Ended
  2022-501263-41-00 4 2023-08-10 Ulcerative Colitis
• MK-7480 Single Ascending Dose Study in Healthy Participants Ended
  2023-505138-88-00 1 2023-08-03 Non-alcoholic steatohepatitis
• Phase 1 Study of PYX-106 in Solid Tumors Ended
  2023-509686-21-00 1 2023-07-05 Solid Tumors
• Phase 1 Study of BMS-986416 with and without Nivolumab in Solid Tumors Ended
  2022-501317-31-00 2 2023-06-29 Solid tumor
• Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP. Ended
  2024-512646-42-00 4 2023-06-27 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S … Ended
  2022-501752-29-00 5 2023-06-15 Hidradenitis Suppurativa
• A clinical study of MK-1403 in healthy men Ended
  2023-504695-23-00 1 2023-06-15 Atherosclerosis
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 5 2023-06-05 Chronic Rhinosinusitis (CRS) in Adults
• Phase 3 Study to Assess Batoclimab in Participants with Active Thyroid Eye Disease Ended
  2024-512649-18-00 5 2023-06-05 Thyroid Eye Disease
• This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended
  2023-504869-23-00 11 2023-05-31 Dermatitis atopic
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer

Showing 769–792 of 904 trials